Cargando…

Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate

Influenza A virus poses a significant threat to public health and the swine industry. Vaccination is the primary measure for controlling the disease, but the effectiveness of vaccines can vary depending on the antigenic match between vaccine strains and circulating strains. In Chile, H1N1pdm09 and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tapia, Rodrigo, Mena, Juan, García, Victoria, Culhane, Marie, Medina, Rafael A., Neira, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548122/
https://www.ncbi.nlm.nih.gov/pubmed/37799404
http://dx.doi.org/10.3389/fvets.2023.1245278
_version_ 1785115208894644224
author Tapia, Rodrigo
Mena, Juan
García, Victoria
Culhane, Marie
Medina, Rafael A.
Neira, Victor
author_facet Tapia, Rodrigo
Mena, Juan
García, Victoria
Culhane, Marie
Medina, Rafael A.
Neira, Victor
author_sort Tapia, Rodrigo
collection PubMed
description Influenza A virus poses a significant threat to public health and the swine industry. Vaccination is the primary measure for controlling the disease, but the effectiveness of vaccines can vary depending on the antigenic match between vaccine strains and circulating strains. In Chile, H1N1pdm09 and other lineages H1N2 and H3N2 have been detected in pigs, which are genetically distinct from the strains included in commercial vaccines. This study aimed to evaluate the cross-protection by commercial vaccines against strains circulating in Chile using the guinea pig model. For this study, four circulating strains [A/swine/Chile/H1A-7/2014(H1N2), A/swine/Chile/H1B-2/2014(H1N2), A/swine/Chile/H1P-12/2015(H1N1), and A/swine/Chile/H3-2/2015(H3N2)] were selected. Guinea pigs were divided into vaccinated and control groups. The vaccinated animals received either a multivalent antigenically heterologous or monovalent homologous vaccine, while the control animals remained unvaccinated. Following vaccination, all animals were intranasally challenged, and nasal wash samples were collected at different time points post-infection. The results showed that the homologous monovalent vaccine-induced hemagglutinin-specific antibodies against the Chilean pandemic H1N1pdm09 strain. However, the commercial heterologous multivalent vaccine failed to induce hemagglutinin-specific antibody titers against the H1N2 and H3N2 challenge strains. Furthermore, the homologous monovalent vaccine significantly reduced the duration of viral shedding and viral titers specifically against the Chilean pandemic H1N1pdm09 strain and heterologous multivalent vaccine only partial. These findings highlight the importance of regularly updating vaccine strains to match the circulating field strains for effective control of swine influenza. Further research is needed to develop vaccines that confer broader protection against diverse strains of swine influenza A virus.
format Online
Article
Text
id pubmed-10548122
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105481222023-10-05 Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate Tapia, Rodrigo Mena, Juan García, Victoria Culhane, Marie Medina, Rafael A. Neira, Victor Front Vet Sci Veterinary Science Influenza A virus poses a significant threat to public health and the swine industry. Vaccination is the primary measure for controlling the disease, but the effectiveness of vaccines can vary depending on the antigenic match between vaccine strains and circulating strains. In Chile, H1N1pdm09 and other lineages H1N2 and H3N2 have been detected in pigs, which are genetically distinct from the strains included in commercial vaccines. This study aimed to evaluate the cross-protection by commercial vaccines against strains circulating in Chile using the guinea pig model. For this study, four circulating strains [A/swine/Chile/H1A-7/2014(H1N2), A/swine/Chile/H1B-2/2014(H1N2), A/swine/Chile/H1P-12/2015(H1N1), and A/swine/Chile/H3-2/2015(H3N2)] were selected. Guinea pigs were divided into vaccinated and control groups. The vaccinated animals received either a multivalent antigenically heterologous or monovalent homologous vaccine, while the control animals remained unvaccinated. Following vaccination, all animals were intranasally challenged, and nasal wash samples were collected at different time points post-infection. The results showed that the homologous monovalent vaccine-induced hemagglutinin-specific antibodies against the Chilean pandemic H1N1pdm09 strain. However, the commercial heterologous multivalent vaccine failed to induce hemagglutinin-specific antibody titers against the H1N2 and H3N2 challenge strains. Furthermore, the homologous monovalent vaccine significantly reduced the duration of viral shedding and viral titers specifically against the Chilean pandemic H1N1pdm09 strain and heterologous multivalent vaccine only partial. These findings highlight the importance of regularly updating vaccine strains to match the circulating field strains for effective control of swine influenza. Further research is needed to develop vaccines that confer broader protection against diverse strains of swine influenza A virus. Frontiers Media S.A. 2023-09-20 /pmc/articles/PMC10548122/ /pubmed/37799404 http://dx.doi.org/10.3389/fvets.2023.1245278 Text en Copyright © 2023 Tapia, Mena, García, Culhane, Medina and Neira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Tapia, Rodrigo
Mena, Juan
García, Victoria
Culhane, Marie
Medina, Rafael A.
Neira, Victor
Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate
title Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate
title_full Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate
title_fullStr Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate
title_full_unstemmed Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate
title_short Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate
title_sort cross-protection of commercial vaccines against chilean swine influenza a virus using the guinea pig model as a surrogate
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548122/
https://www.ncbi.nlm.nih.gov/pubmed/37799404
http://dx.doi.org/10.3389/fvets.2023.1245278
work_keys_str_mv AT tapiarodrigo crossprotectionofcommercialvaccinesagainstchileanswineinfluenzaavirususingtheguineapigmodelasasurrogate
AT menajuan crossprotectionofcommercialvaccinesagainstchileanswineinfluenzaavirususingtheguineapigmodelasasurrogate
AT garciavictoria crossprotectionofcommercialvaccinesagainstchileanswineinfluenzaavirususingtheguineapigmodelasasurrogate
AT culhanemarie crossprotectionofcommercialvaccinesagainstchileanswineinfluenzaavirususingtheguineapigmodelasasurrogate
AT medinarafaela crossprotectionofcommercialvaccinesagainstchileanswineinfluenzaavirususingtheguineapigmodelasasurrogate
AT neiravictor crossprotectionofcommercialvaccinesagainstchileanswineinfluenzaavirususingtheguineapigmodelasasurrogate